Fierce Healthcare

United Therapeutics Launches Living PAH Program for Patients with Pulmonary Arterial Hypertension

SILVER SPRING, Md.--(BUSINESS WIRE)-- United Therapeutics Corporation and Lung Rx, LLC announced today the launch of a nationwide support program for patients who are currently prescribed a United ...
Monthly Prescribing Reference

Subcutaneous Delivery System for Remodulin Cleared by FDA

The FDA has cleared the Unity Subcutaneous Delivery System for Remodulin (treprostinil) Injection, also known as the RemUnity system. The Food and Drug Administration (FDA) has cleared the Unity ...
Nasdaq

United Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin®

RESEARCH TRIANGLE PARK, N.C. and MANCHESTER, N.H., Feb. 24, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and DEKA Research & Development Corp. today announced receipt of an ...
FierceBiotech

Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Route

First Presentation of Full Data Set from the TRIUMPH-1 Trial of Inhaled Treprostinil SILVER SPRING, Md., May 21, 2008 -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary ...
The Trentonian

Sandoz announces generic Treprostinil Injection now also available for subcutaneous route of administration to treat PAH patients in US

PRINCETON, N.J., May 24, 2021 /PRNewswire/ — Sandoz today announced Treprostinil Injection, a generic Remodulin (R), is now also available for subcutaneous (“SC”) administration to treat patients ...
Seeking Alpha

Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)

Liquidia and Sandoz have also extended the term of their promotion agreement for Treprostinil Injection until 2032 MORRISVILLE, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (Liquidia ...